|
Re: Trial Status
|
5
|
Resverlogix Corp.
|
Jul 21, 2021 08:14PM
|
|
Re: Trial Status
|
1
|
Resverlogix Corp.
|
Jul 22, 2021 10:08AM
|
|
Re: Trial Status
|
4
|
Resverlogix Corp.
|
Jul 26, 2021 10:10AM
|
|
Re: Trial Status
|
2
|
Resverlogix Corp.
|
Jul 22, 2021 08:20PM
|
|
Re: Trial Status
|
3
|
Resverlogix Corp.
|
Jul 20, 2021 06:19PM
|
|
Re: Trials and statistics, next steps
|
3
|
Resverlogix Corp.
|
Feb 11, 2020 04:21PM
|
|
Re: TRIALS SITE/ SHOWS TWO APPROVED TRIALS
|
2
|
Zenith Epigenetics
|
Jun 16, 2016 08:35AM
|
|
Re: TRIALS SITE/ SHOWS TWO APPROVED TRIALS
|
3
|
Zenith Epigenetics
|
Jun 16, 2016 10:21AM
|
|
Re: Trillium
|
2
|
Zenith Epigenetics
|
Aug 26, 2021 07:18PM
|
|
Re: Trillium
|
5
|
Zenith Epigenetics
|
Aug 25, 2021 11:20AM
|
|
Re: Trillium
|
4
|
Zenith Epigenetics
|
Aug 26, 2021 11:11AM
|
|
Re: trying to making sense
|
7
|
Resverlogix Corp.
|
Mar 09, 2022 11:55AM
|
|
Re: TSX Review
|
3
|
Resverlogix Corp.
|
Mar 15, 2018 01:18PM
|
|
Re: TSX Review
|
2
|
Resverlogix Corp.
|
Mar 13, 2018 09:02PM
|
|
Re: Two articles - Apabetalone for Colon Cancer?
|
4
|
Resverlogix Corp.
|
Jul 09, 2021 10:50AM
|
|
Re: Two investor conferences May 2
|
4
|
Resverlogix Corp.
|
May 01, 2016 03:39PM
|
|
Re: Two more clinical study sites added to the ZEN-3694/enzalutamid... mCRPC trial
|
6
|
Zenith Epigenetics
|
Sep 05, 2018 03:50PM
|
|
Re: two things most believe
|
|
Resverlogix Corp.
|
Sep 08, 2021 06:11PM
|
|
Re: Underwhelmed
|
1
|
Resverlogix Corp.
|
Aug 30, 2017 08:51AM
|
|
Re: Upcoming RVX presentations, human blood microarray & babbling on FACET analysis
|
2
|
Resverlogix Corp.
|
Jul 24, 2015 05:38PM
|
